Differences in the expression of 4 progesterone receptor antibodies EP2, SP2, 1E2, and 16 in non-specific invasive breast cancers

Sanyan LI; Meisong ZHENG; Yupeng CHEN; Sheng ZHANG; Xianrong ZHOU; Linying CHEN

doi:10.16016/j.1000-5404.201912016

您当前的位置：

首页 >

文章列表页 >

Differences in the expression of 4 progesterone receptor antibodies EP2, SP2, 1E2, and 16 in non-specific invasive breast cancers

Clinical Medicine | 更新时间：2026-01-09

- Differences in the expression of 4 progesterone receptor antibodies EP2, SP2, 1E2, and 16 in non-specific invasive breast cancers
- Journal of Third Military Medical University Vol. 42, Issue 10, Pages: 1042-1046(2020)
- 作者机构：
  
  1.433100 湖北潜江，潜江市中心医院病理科
  2.362801 福建泉州，福建省泉州市泉港区医院病理科
  3.350005 福州，福建医科大学附属第一医院病理科
- 作者简介：
- 基金信息：
  
  the Educational Research Project for Young and Middle-aged Teachers of Fujian Education Department(JT180185)
- DOI：10.16016/j.1000-5404.201912016
  CLC： R392.11;R730.23;R737.9
- Received：02 December 2019，
  
  Revised：2020-03-10，
  
  Published：30 May 2020
- 稿件说明：
移动端阅览
Sanyan LI, Meisong ZHENG, Yupeng CHEN, et al. Differences in the expression of 4 progesterone receptor antibodies EP2, SP2, 1E2, and 16 in non-specific invasive breast cancers[J]. Journal of Third Military Medical University, 2020, 42(10): 1042-1046.
DOI：

Sanyan LI, Meisong ZHENG, Yupeng CHEN, et al. Differences in the expression of 4 progesterone receptor antibodies EP2, SP2, 1E2, and 16 in non-specific invasive breast cancers[J]. Journal of Third Military Medical University, 2020, 42(10): 1042-1046. DOI： 10.16016/j.1000-5404.201912016.

摘要

目的

评估4种孕激素(progesterone receptor，PR)抗体(EP2、SP2、1E2、16)在非特殊型浸润性乳腺癌(non-specific invasive breast cancers

NSIBCs)组织中的表达，为PR判读及NSIBCs患者治疗筛选出最佳抗体。

方法

采用免疫组化法检测195例NSIBCs组织芯片中4种PR抗体的表达情况，分析比较与雌激素(estrogen receptor，ER)抗体表达构成比、着色细胞百分比、染色强度、Allred score(A-score)评分及4个抗体一致性等指标。

结果

195例NSIBCs中4种PR抗体与ER的构成比(ER±/PR±)之间差异无统计学意义(

0.05)。不考虑ER表达，4种PR抗体同时阳性或阴性(PR+/-)NSIBCs比例较高(81.54%~90.77%)，且相互的一致性较好(κ值为0.634~0.804)。进一步分析4种PR抗体的肿瘤细胞平均着色细胞数、平均阳性细胞百分比评分、平均染色强度、平均A-score等指标，显示1E2各项指标明显高于其他3种抗体(

0.05)，而EP2、SP2、16三者之间差异无统计学意义(

0.05)。

结论

NSIBCs中1E2着色阳性率及强度等均高于EP2、SP2、RP16，是较理想的PR抗体。

Abstract

Objective

To detect the expression of 4 progesterone receptor (PR) antibodies (EP2

SP2

1E2

and 16) in non-specific invasive breast cancer (NSIBCs) and identify the optimal antibody for PR analysis and treatment planning for NSIBCs.

Methods

Immunohistochemistry was used to detect the expression of the 4 PR antibodies in a tissue microarray consisting of 195 tissue specimens of NSIBCs

and their constituent ratios with the expression of estrogen receptor (ER)

the percentages of stained cells

staining intensity

Allred score (A-score) and consistency were compared.

Results

The constituent ratios of the 4 PR antibodies with ER (ER±/PR±) did not differ significantly in the 195 cases of NSIBCs (

0.05). Regardless of the status of ER expression

the cases showed high rates of positivity or negativity for all the 4 PR antibodies at the same time (81.54%~90.77%) with good consistencies among the 4 antibodies (κ=0.634~0.804). Further analysis of the average number of stained cells

percentage of positive cells

staining intensity

and A-score of the 4 PR antibodies showed that all these indicators were significantly higher for 1E2 than for EP2

SP2

and 16 (

0.05)

and were not significantly differ

ent among the latter 3 antibodies (

0.05).

Conclusion

1E2 has a higher positivity rate and expression intensity in NSIBCs than EP2

SP2 and RP16

and thus can serve as an ideal PR antibody for clinical pathology tests.

关键词

Keywords

references

[Global Burden of Disease Cancer Collaboration. FITZMAURICE C, AKINYEMIJU T F, et al . Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: A systematic analysis for the global burden of disease study[J ] . JAMA Oncol, 2018, 4(11): 1553-1568. DOI: 10.1001/jamaoncol.2018.2706 http://dx.doi.org/10.1001/jamaoncol.2018.2706 ..

HWANG K T, KIM J, JUNG J, et al . Impact of breast cancer subtypes on prognosis of women with operable invasive breast cancer: A population-based study using SEER database[J ] . Clin Cancer Res, 2019, 25(6): 1970-1979. DOI: 10.1158/1078-0432.CCR-18-2782.

PRAT A, CHEANG M C, MARTÍN M, et al . Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer[J ] . J Clin Oncol, 2013, 31(2): 203-209. DOI: 10.1200/JCO.2012.43.4134.

PRAT A, PINEDA E, ADAMO B, et al . Clinical implications of the intrinsic molecular subtypes of breast cancer[J ] . Breast, 2015, 24(suppl 2): S26-S35. DOI: 10.1016/j.breast.2015.07.008.

BURSTEIN H J, LACCHETTI C, ANDERSON H, et al . Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline f ocused update[J ] . J Clin Oncol, 2019, 37(5): 423-438. DOI: 10.1200/JCO.18.01160.

HWANG K T, KIM J, JUNG J, et al . Long-term prognostic effect of hormone receptor subtype on breast cancer[J ] . Breast Cancer Res Treat, 2020, 179(1): 139-151. DOI: 10.1007/s10549-019-05456-w.

NORDENSKJÖLD A, FOHLIN H, FORNANDER T, et al . Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer[J ] . Breast Cancer Res Treat, 2016, 160(2): 313-322. DOI: 10.1007/s10549-016-4007-5.

LUMACHI F, SANTEUFEMIAD A, BASSO S M, et al . Current medical treatment of estrogen receptor-positive breast cancer[J ] . World J Biol Chem, 2015, 6(3): 231-239. DOI: 10.4331/wjbc.v6.i3.231.

TROXELL M L, LONG T, HORNICK J L, et al . Comparison of estrogen and progesterone receptor antibody reagents using proficiency testing data[J ] . Arch Pathol Lab Med, 2017, 141(10): 1402-1412. DOI: 10.5858/arpa.2016-0497-OA.

IBRAHIM M, DODSON A, BARNETT S, et al . Potential for false-positive staining with a rabbit monocl onal antibody to progesterone receptor (SP2): findings of the UK National External Quality Assessment Scheme for Immunocytochemistry and FISH highlight the need for correct validation of antibodies on introduction to the laboratory[J ] . Am J Clin Pathol, 2008, 129(3): 398-409. DOI: 10.1309/2YXRLEQVPPNRWHGA.

LAKHANI S R, ELLIS I O, SCHNITT S J, et al . WHO Classification of Tumours of the Breast. 4th ed[M ] . International Agency for Research on Cancer. Lyon: IARC press, 2012.

RHODES A, SARSON J, ASSAM E E, et al . The reliability of rabbit monoclonal antibodies in the immunohistochemical assessment of estrogen receptors, progesterone receptors, and HER2 in human breast carcinomas[J ] . Am J Clin Pathol, 2010, 134(2): 621-632. DOI: 10.1309/AJCPOG3O3KTPZQNK.

BAE Y K, GONG G, KANG J, et al . Hormone receptor expression in invasive breast cancer among Korean women and comparison of 3 antiestrogen receptor antibodies: a multi-institutional retrospective study using tissue microarrays[J ] . Am J Surg Pathol, 2012, 36(12): 1817-1825. DOI: 10.1097/PAS.0b013e318267b012.

HUANG H J, NEVEN P, DRIJKONINGEN M, et al . Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer[J ] . J Clin Pathol, 2005, 58(6): 611-616. DOI: 10.1136/jcp.2004.022772。

CALHOUN B C, MOSTELLER B, WARREN D, et al . Analytical and clinical performance of progesterone receptor antibodies in breast cancer[J ] . Ann Diagn Pathol, 2018, 35: 21-26.DOI: 10.1016/j.anndiagpath.2018.02.007.

水若鸿, 杨文涛.乳腺癌雌、孕激素受体免疫组织化学检测中的常用抗体[J].中华病理学杂志, 2015, 44(4): 229-231. DOI:10.3760/cma.j.issn.0529-5807.2015.04.003.

SHUI R H, YANG W T. Frequently used antibodies of estrogen and progesterone receptors in breast cancers by immunohistochemistry[J]. Chin J Pathol, 2015, 44(4): 229-231. DOI: 10.3760/cma.j.issn.0529-5807.2015.04.003.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Correlation of ultrasonographic characteristics with expression of ER, PR and CerbB-2 in breast cancer

Correlation of types of residual tumor with expressions of ER, PR and HER-2 after neoadjuvant chemotherapy in breast cancer

Circulating tumor cells and clinicopathologic characteristics of primary tumor of breast cancer patients: report of 128 cases

Expressions of estrogen receptor and progesterone receptor in elderly breast cancer patients and its relationship with clinical pathology

A novel estrogen receptor expression stratification (low/moderate/high) based on Chinese population provides more accurate prognosis prediction for HR⁺/HER2^- early breast cancer patients

Related Author

邱敏

陈涛

何琳

徐乐

齐晓伟

王姝姝

张毅

陈庆秋

Related Institution

Department of Breast and Thyroid Surgery， First Affiliated Hospital， Army Medical University （Third Military Medical University）

Department of Biochemistry and Molecular Biology, Institute of Molecular Medicine and Cancer, College of Basic Medical Sciences, Chongqing Medical University

⁰